However, the results support further investigation of GLP-1RAs as potential treatments for AUD, and larger randomized controlled trials are needed to clarify their mechanisms and evaluate their potential efficacy in people with AUD
Glutathione is a versatile skincare ingredient suitable for most skin types, particularly those with hyperpigmentation, uneven skin tone, or signs of ageing
The relationship between B12 and bowel changes is typically indirect, relating more to the supplement formulation, excipients (inactive ingredients), or underlying health conditions rather than the vitamin itself
The public are encouraged to report any medicines and devices adverse reactions over to MHRA via the Yellow Card Reporting System and to call NHS 111 if medical assistance is required
Findings: RCTSURMOUNT-2 trial - Tirzepatide vs Placebo for Weight Loss in Diabetes, Lancet (2023) [PubMed abstract] Design: Randomized, placebo-controlled trial (N=938 | length = 72 weeks) in overweight diabetics (mean BMI 36 | mean A1C 8.02%) Treatment: Tirzepatide 10 mg once weekly vs Tirzepatide 15 mg once weekly vs Placebo Primary outcome: Coprimary endpoints were the percent change in body weight from baseline and body weight reduction of 5% or higher Results: Primary outcome (% reduction in weight): Tirzepatide 10 mg - 12.8%, Tirzepatide 15 mg - 14.7%, Placebo - 3.2% (p 35 - 68.9% Randomized treatment groups Group 1 (374 patients): Tirzepatide titrated to the maximum tolerated dose of 10 mg or 15 mg once weekly Group 2 (376 patients): Semaglutide titrated to the maximum tolerated dose of 1.7 mg or 2.4 mg once weekly Tirzepatide was initiated at a dose of 2.5 mg once weekly, and the dose was increased by 2.5 mg every 4 weeks until a maximum tolerated dose of 10 mg or 15 mg was reached
